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The ﬁrst liposomal formulation of cisplatin to be evaluated clinically was SPI-077. Although the formulation demonstrated
enhanced cisplatin tumor accumulation in preclinical models it did not enhance clinical eﬃcacy, possibly due to limited cisplatin
release from the formulation localized within the tumor. We have examined a series of liposomal formulations to address the in
vivorelationshipbetweencisplatinreleaserateandformulationeﬃcacyintheP388murineleukemiamodel.Thebaseformulation
of phosphatidylcholine: phosphatidylglycerol: cholesterol was altered in the C18 and C16 phospholipid content to inﬂuence
membraneﬂuidityandtherebyimpactingdrugcirculationlifetimeanddrugretention.Phasetransitiontemperatures(Tm)rang ed
from 42–55◦C. The high Tm formulations demonstrated enhanced drug retention properties accompanied by low antitumor
activitywhilethelowestTm formulationsreleasedthedrugtoorapidlyintheplasma,limitingdrugdeliverytothetumorwhichalso
resulted in low antitumor activity. A formulation composed of DSPC:DPPC:DSPG:Chol; (35:35:20:10) with an intermediate
drug release rate and a cisplatin plasma half-life of 8.3 hours showed the greatest antitumor activity. This manuscript highlights
the critical role that drug release rates play in the design of an optimized drug delivery vehicle.
1.Introduction
Cisplatin or cis-diamminedichloroplatinum (II) belongs to
a family of platinum-containing complexes that are used
clinically to treat cancer and include carboplatin, oxaliplatin,
and nedaplatin. Cisplatin is a widely used cytotoxic agent
approved in the treatment of bladder, ovarian, testicular,
cervical, head and neck, and nonsmall cell lung cancer [1–3].
Cisplatin was ﬁrst documented in 1847 by M. Peyrone, and
it was approved by FDA for a variety of cancers in 1978. The
mode of action of cisplatin depends on the rate of hydrolysis
of the chloride groups of the complex. Upon entering the
cell, the neutral cisplatin molecule undergoes hydrolysis,
in which a chlorine ligand is replaced by a molecule of
water (termed aquation), generating a positively charged
species. The resulting hydrolysis product is believed to be
the active species, interacting with nucleophilic molecules
including DNA [4], RNA, and protein. More speciﬁcally, the
interactions result in interstrand and intrastrand cross-links
thateﬀectivelyhaltDNA,RNA,andproteinsynthesisleading
to the activation of the apoptotic cascade [5, 6]. Although
cisplatin is a highly eﬀective anticancer agent, it is noted for
severe side eﬀects including renal toxicity, gastrointestinal
toxicity, nephrotoxicity, ototoxicity, and optic neuropathy
which limits its use in the clinic [7–10].
Drug delivery vehicles, such as liposomes, have been
employed to reduce the dose-limiting nephrotoxicity of
cisplatin [10, 11]. Currently, there are no FDA-approved
liposomal cisplatin formulations available; however, SPI-077
and Lipoplatin formulations have been tested in clinical
trials [12–14]. SPI-077 is a sterically stabilized liposomal
cisplatin formulation containing hydrogenated soy phos-
phatidylcholine, cholesterol, and methoxypolyethylene gly-
col (mPEG-DSPE) at a 51:44:5 molar ratio [12, 15, 16].
Although the formulation exhibited prolonged circulation in
blood and was very well tolerated [16], it had very limited
therapeutic activity in a Phase II clinical study in NSCLC,
with an overall response rate of 4.5% [12]. The release
of platinum from the SPI-077 formulation at the tumor
site was subsequently investigated by Zamboni et al. [17]2 Chemotherapy Research and Practice
using microdialysis. In this study, B16 melanoma tumor
homogenates were assayed for platinum accumulation fol-
lowing intravenous administration of SPI-077 or cisplatin.
In the case of SPI-077-treated mice, approximately 4-fold
higher platinum levels were associated with the tumors
than that of cisplatin. However, analysis of tumor extra-
cellular ﬂuid by microdialysis revealed no detectable levels
of unbound platinum in SPI-077-treated mice indicating
very little release of cisplatin from the liposomes within the
tumor. As a measure of cisplatin activity within the tumor,
platinum DNA adduct analysis revealed approximately 4-
fold lower adduct formation with SPI-077 compared to
cisplatin. These results indicate that the poor clinical eﬃcacy
observed with SPI-077 is likely the result of low cisplatin
release from the liposomes at the tumor site. Taken together,
enhanced platinum delivery to the tumor site through
improved lipid retention does not lead to improved ther-
apeutic eﬃcacy, due to decreased tumor exposure to free
agent.
Lipoplatin, another liposomal cisplatin formulation, is
composed of dipalmitoyl phosphatidyl glycerol (DPPG), soy
phosphatidyl choline, cholesterol, and mPEG-DSPE [13, 14,
18, 19]. It is currently undergoing a number of Phase II and
Phase III clinical trials in combination with other cytotoxic
agents such as gemcitabine, 5-ﬂuorouracil, and vinorelbine,
wherelipoplatinisdemonstratingsubstantiallyreducedrenal
toxicity, peripheral neuropathy, ototoxicity, and myelotoxic-
ity [14, 19]. As with SPI-077, enhanced retention of cisplatin
may improve tolerability of the liposomal cisplatin formula-
tion but may also result in decreased antitumor activity.
To determine if the drug release rate plays a critical role
in the overall therapeutic activity of a cisplatin formulation,
a series of liposomes were prepared. The base formulation
chosen for this study was composed of phosphatidylcholine
(PC), phosphatidylglycerol (PG), and cholesterol (Chol) at a
7:2:1 mole ratio since this composition was previously used
to control the release rates of irinotecan, ﬂoxuridine, cytara-
bine, and daunorubicin [20, 21]. Through small changes
in the phospholipid acyl chain composition, we were able
to generate a panel of cisplatin formulations with diﬀerent
release rates without changing the phospholipid molar
ratio of the formulation. As the percentage of dipalmitoyl
acyl chains increased and distearoyl decreased, there was a
corresponding decrease in the thermal melting point of the
formulation and an enhancement in cisplatin release rate
in vivo. This series of liposomal formulations was evaluated
for therapeutic activity in the P388 murine lymphocytic
leukemia model. Based on the eﬃcacy results, an optimal
cisplatin release rate was identiﬁed.
2.MaterialsandMethods
2.1. Reagents. 1,2-distearoyl-sn-glycero-3-phosphatidylcho-
line(DSPC),1,2-dipalmitoyl-sn-glycero-3-phosphatidylcho-
line (DPPC), and 1,2-distearoyl-sn-glycero-3-phosphatidy-
lglycerol (DSPG) were purchased from Lipoid GMBH (Lud-
wigshafen, Germany). Cholesterol (CHOL) was obtained
from Solvay Pharmaceuticals BV (Weesp, Netherlands). 3H-
cholesteryl hexadecyl ether (CHE) was purchased from
Perkin-Elmer Life Sciences (Woodbridge Ontario, Canada).
Cisplatin lyophilized powder was purchased from PolyMed
Therapeutics, Inc. (Houston, Texas, USA). All other chem-
icals were purchased from Sigma Chemical Co. (St. Louis,
MO, USA).
2.2. Liposome Preparation. All liposome formulations were
prepared by the extrusion technique. Brieﬂy, the lipids were
dissolved in chloroform/methanol/water (5:1:0.1, v/v/v)
and mixed together at the indicated molar ratio. 3H-
CHE was added to the formulations as a nonexchangeable,
nonmetabolized lipid marker. The solvent mixture was
evaporated under a stream of nitrogen gas and the sample
was placed under high vacuum for 3 hours. The lipid ﬁlms
were rehydrated in 150mM saline by gentle mixing at 70◦C.
Thenewlyformedmultilamellarvesicles(MLVs)werepassed
2 times through an extruding apparatus (Northern Lipids
Inc.,Vancouver,BC,Canada)containingtwostacked200nm
and 8 times through 100nm polycarbonate ﬁlters (Northern
Lipids Inc., Vancouver, BC, Canada). The extrusion was
c a rri edo u ta t7 0 ◦C. The mean diameter and size distribution
of each liposome preparation were analyzed by quasielastic
lightscatteringNICOMPmodel380submicronparticlesizer
(Paciﬁc Scientiﬁc, Santa Barbara, CA, USA), and was typi-
cally 100 ± 20nm by volume weighting. Cisplatin was pas-
sivelyloadedintoextrudedliposomesaspreviouslydescribed
[22]. Brieﬂy, a ﬁnal solution containing 20mg/ml lipid,
7.5mg/ml cisplatin, and 7.5% ethanol was mixed and heated
for 1 hour at 60◦C. The ethanol and the unencapsulated
cisplatin were removed by tangential ﬂow ﬁltration through
polysulfone hollow ﬁber columns (500kD, GE Healthcare)
against 10 wash volumes of 150mM saline. In the case of
the DSPC/Chol formulation, however, cisplatin could not be
eﬃcientlyencapsulatedintotheformulationsafterextrusion,
presumablyduetothehighcholesterolcontentoftheformu-
lation. As a result, cisplatin was incorporated in this formu-
lationbyextrudinginthepresenceofthedrug.Althoughthis
formulation was included in the pharmacokinetic studies,
it was not included in the eﬃcacy due to concerns related
to the stability of cisplatin following high temperature
and pressure exposure. Diﬀerential scanning calorimetry
(DSC) measurements were performed using a VP-DSC
Microcalorimeter (MicroCal, Northampton, MA) with a
scan rate of 60◦C/hr. Liposomes were diluted to 5–20mg/ml
in saline, and the reference cell was ﬁlled with degassed
saline. Buﬀer baselines were subtracted from the liposome
scans, and the main gel to liquid-crystalline phase transition
temperature was determined and recorded as the (Tm) of the
formulation. Data were analyzed using ORIGIN software.
2.3. Pharmacokinetic Analysis and Biodistribution. All ani-
mal experiments were conducted under the guidance of
the UBC animal care committee. BDF-1 mice (3 mice
per group) were injected with 3mg/kg liposomal cisplatin
into the lateral tail vein. At various time points, up to
48 hours after drug administration, blood was collected
by cardiac puncture and collected into EDTA-containing
microtainer tubes, cooled on ice and centrifuged at 900
× gf o r1 0 m i na t4 ◦C. Platinum levels were analyzedChemotherapy Research and Practice 3
Table 1: Correlation between membrane composition and pharmacokinetics parameters of cisplatin-containing liposomes.
Formulation % DS % DP Tm (◦C) Cisplatin
T1/2 (h)
AUMC cisplatin
(mg·h2/mL)
Lipid T1/2
(h)
AUMC lipid
(mg·h2/mL)
DSPC:CHOL (55:45) 55 0 55.3 18.9 82.6 23.5 12894.5
DSPC:DSPG:Chol (7:2:1) 90 0 54.9 14.7 27.8 28.0 9892.3
DSPC:DPPC:DSPG:Chol(6:1:2:1) 80 10 52.5 11.6 22.1 29.3 11836.8
DSPC:DPPC:DSPG:Chol (35:35:20:10) 55 35 48.8 8.3 6.6 15.3 2953.0
DSPC:DPPC:DPPG:Chol (35:35:20:10) 35 55 45.5 6.8 4.8 16.6 3511.0
DPPC:DPPG:Chol (7:2:1) 0 90 42.2 4.5 1.7 9.3 1058.9
The T1/2 and AUMC values presented in this table were based on plasma measurements recorded within the ﬁrst 24 hours of administration.
by atomic absorption spectroscopy (Varian SpectrAA-240
Zeeman Graphite Furnace atomic absorption spectrometer;
Varian, Canada Inc. ST-Laurent, Quebec, Canada), and
lipid concentration was determined by quantifying tracer
quantities of 3H-CHE by liquid scintillation counting (LS
6500 Multi Purpose Scintillation Counter; Beckman Coulter
Canada Inc., Mississauga, Ontario, Canada). The plasma
elimination data was modeled by PK Solutions (Summit
Research Services, Montrose, Colorado, USA) to calculate
pharmacokinetic parameters including half-life (T1/2)a n d
area-under-the-moment curve (AUMC0-tlast).
For biodistribution studies, spleen, liver, and kidneys
of the injected mice (3 mice per group) were collected up
to 96 hours after drug administration. The tissues were
e x c i s e di n t op r e w e i g h e dt u b e sa n ds t o r e da t−80◦C. For
analysis of total platinum, tissue samples were thawed and
homogenized in 0.9% sterile saline (tissue: 0.9% NaCl at
1:5w/v).Homogenate(100µl) was added to 100µl of 70%
nitric acid and incubated at 70◦C for 2 hours. The samples
were cooled, diluted with 1% nitric acid and analyzed by
graphite furnace atomic absorption spectrometer (AA240Z,
Varian, Mulgrave, Victoria, Australia) containing a GTA 120
Zeemangraphitetubeatomizer.Ptabsorbancewasmeasured
at a wavelength of 265.9nm.
2.4. In Vivo Eﬃcacy Studies and Tumor Accumulation
Studies. Eﬃcacy studies were conducted in female BDF-
1 mice (8 mice per group) injected i.p. with 500µlo f
1 × 106 P388 murine lymphocytic leukemia cells which
were obtained from the National Cancer Institute tissue
repository (Bethesda, Maryland, USA) and propagated in
vivo as described previously [23]. Intravenous liposome
administration commenced 24 hours after tumor cell inoc-
ulation. Mice were monitored daily for signs of stress and
toxicity. Animals that showed signs of illness due to tumor
progression were terminated, and the day of death was
recorded as the following day. The treatment (T) and control
(C) group lifespan were determined the day in which the last
mouse in the group died. The percent increased lifespan (%
ILS) was calculated as (T−C)/C.
3. Results andDiscussion
3.1. Cisplatin Plasma Elimination as a Function of Lipid
Composition. We evaluated the eﬀect of diﬀerent membrane
compositions on the drug release properties of liposomes
composed of phosphatidylcholine (PC), phosphatidylglyc-
erol (PG), and cholesterol. The compositions were varied
by evaluating 1,2-distearoyl (DS) or 1,-2-dipalmitoyl (DP)
versions of PC and PG combined at diﬀerent ratios while
the cholesterol content was ﬁxed at 10mol%. The increase
in molar % DS content in membrane composition of
these low-cholesterol liposomes corresponded to an increase
in membrane transition temperature (Tm)( Table 1). All
formulations showed a single transition temperature peak
by DSC indicating good lipid mixing in the bilayer and an
absence of phospholipid domain formation. Cisplatin was
loaded into the formulations using a postextrusion method
[22] to avoid exposing the drug to high temperatures and
pressuresrequiredduringliposomeformation.Theclearance
proﬁles of the formulations were compared to conventional
DSPC:Chol (55:45 mol%) liposomes, known for their
slow clearance and enhanced drug retention properties.
As can be seen from the plasma elimination of cisplatin
(Figure 1(a)), the highest circulating plasma levels were
observed with the conventional DSPC:Chol formulation
where levels approaching 50% of the injected dose were
still observed at 24 and 48 hours after administration. As
previously predicted, the DSPC/Chol formulation showed
very little change in the cisplatin-to-lipid ratio over 48
hours (Figure 1(c)) indicating that only a small percentage
of cisplatin is released from this formulation in vivo.
For the low-cholesterol formulations a decrease in molar
% DS corresponded to lower cisplatin levels in plasma.
(Figure 1(a)). From these data various pharmacokinetic
parameters were calculated including cisplatin half-life,
cisplatin AUC, lipid half-life, and lipid AUC (Table 1). The
pharmacokinetic results revealed a general trend where
increasing DP content resulted in decreased cisplatin and
lipid half-lives. The decreased lipid half-life may be the
result of more ﬂuid liposomal membranes binding higher
amounts of serum protein. This has been shown previ-
ously to enhance liposomal clearance. To determine if the
decreasing plasma cisplatin levels were simply the result of
enhanced liposome clearance, changes in the drug-to-lipid
ratio were calculated and plotted (Figure 1(c)). Based on
these composite results, there is a clear diﬀerence in the
drug retention properties of the various formulations. As
with the cisplatin and lipid clearance, an increase in the
DP content resulted in enhanced drug leakage. The eﬀect4 Chemotherapy Research and Practice
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Figure 1: Percent of injected dose for cisplatin (a), lipid (b) and percent initial cisplatin/lipid ratio (c) in plasma following i.v.
administration of cisplatin containing liposomes into BDF-1 mice. The formulation compositions: DSPC:DSPG:CHOL (7:2:1)
(•); DSPC:DPPC:DSPG:CHOL (6:1:2:1) (◦); DSPC:DPPC:DSPG:CHOL (35:35:20:10) (); DSPC:DPPC:DPPG:CHOL
(35:35:20:10) (), DPPC:DPPG:CHOL (7:2:1) (); DSPC:CHOL (55:45) (gray circle); and free cisplatin (), were all administered
at a cisplatin dose of 3mg/kg (n = 3, Mean ± SD). Mouse plasma was collected at 0.5, 1, 2, 4, 8, 16, 24, and 48 hours after administration.
The platinum concentration was determined by atomic absorption spectroscopy and the lipid by scintillation counting.
of lipid composition (percent DS content) on the Tm of
the liposomal carrier and on cisplatin half-life was plotted
in Figure 2. This ﬁgure demonstrates a clear relationship
between the membrane composition and platinum plasma
levels. Although the set of ﬁve low-cholesterol formulations
showed only a 12.7◦C range (54.9–42.2◦C) in transition tem-
peratures, large eﬀects were observed in the pharmacokinetic
properties of these formulations. When comparing the most
divergent formulations DSPC/DSPG/Chol (7:2:1, 90% DS)
versus DPPC/DPPC/Chol (7:2:1, 90% DP), the DS based
formulation circulated for 3-fold longer, and enhanced
cisplatin circulation by 3.26-fold, resulting in a 16.3-fold
improvement in cisplatin AUC. Even more surprising was
the observation that formulations with moderately diﬀerent
lipid clearance proﬁles and transition temperatures could
have dramatically diﬀerent release rates. For example, when
comparingDSPC/DSPG/Chol(7:2:1,90%DS)toablended
formulation of DSPC:DPPC:DSPG:Chol (35:35:20:10,
55% DS), the cisplatin half-life is 1.8-fold faster in the
blended composition which decreased the cisplatin AUC by
4.2-fold. These results highlight how small changes in the
membrane transition temperature can have a dramatic eﬀect
on in vivo pharmacokinetics.
3.2. Impact of Cisplatin Release Rate on P388 Eﬃcacy.
All of the low-cholesterol formulations were evaluated for
eﬃcacy in the P388 murine lymphocytic leukemia model
to determine if the diﬀerent pharmacokinetic properties of
the formulations would have an impact on the therapeutic
activity of cisplatin. We compared the overall survival rates
for each formulation to saline and calculated the percentage
increased life span or %ILS. In Figure 3 the %ILS for each
formulation is plotted along with its respective cisplatin
releasehalf-life.ItisclearthatenhancingcisplatincirculationChemotherapy Research and Practice 5
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Figure 2: The eﬀect of % DS content on the transition temperature
(Tm) of liposomal carrier (•) and on cisplatin half-life (◦)i nt h e
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Figure 3: Cisplatin half-life () and the corresponding percent
of increased lifespan (%ILS) (gray square) from the P388 murine
lymphocytic leukemia model are plotted as a function of the
liposomal membrane composition. Mice (n = 8) bearing P388
tumors received intravenous injections of liposomal cisplatin
formulations at MTD doses on a Q4D × 3 dosing schedule.
lifetime did not result in improved cisplatin eﬃcacy in
the P388 model. In fact, the formulation with the longest
cisplatin half-life (DSPC:DSPG:Chol 7:2:1 at 14.7 hours),
haslowest%ILScomparedtoaformulationwithaninterme-
diate half-life (DSPC:DPPC:DSPG:Chol; 35:35:20:10 at
8.3 hours) and the highest %ILS. The second lowest %ILS
values were observed for DPPC:DPPG:Chol which had the
shortest cisplatin half-life of 4.5 hours. Taken together, high
and low cisplatin release rates translated into poor biological
performance.
3.3. Biodistribution of Liposomal Cisplatin. One of the major
dose-limiting toxicities associated with the use of cisplatin is
nephrotoxicity resulting from the accumulation of cisplatin
within the kidney. To determine if the liposomal formula-
tions of cisplatin had an impact on drug biodistribution,
we compared the most and least therapeutically active
formulations to free cisplatin at an equivalent drug dose.
At various times after injection, kidney as well as the
spleenandliver(establishedsitesofliposomalaccumulation)
were harvested and assayed for platinum levels (Figure 4).
Unfortunately, due to the reactivity of cisplatin, tissue
extraction and analysis of intact drug by HPLC was not
possible. As a result, we measured tissue levels of platinum
using atomic adsorption spectroscopy as a marker for
cisplatin content. Platinum accumulation in all 3 organs
was higher following the injection of liposomal cisplatin
compared to free cisplatin injection. The slow-releasing
DSPC:DSPG:Chol (7:2:1) formulation had the highest
levels of platinum in both the liver and spleen compared to
the DSPC:DPPC:DSPG:Chol (35:35:20:10) formulation
and free drug. Since the liver and spleen typically account for
the majority of liposomal accumulation, it is not surprising
that a slow-releasing formulation increased cisplatin delivery
to these organs. In the case of the kidney, however, platinum
levels were similar between both the formulations and the
free drug. A slight increase in kidney levels over time in
the blended formulation may represent an accumulation
of free cisplatin released from the liposome as opposed to
enhanced liposomal accumulation over time. Comparable
kidney accumulation may account for the similarity in MTD
doses of all three drug forms.
4. Conclusion
It is generally believed that increasing the retention of a drug
within a delivery vehicle will result in enhanced drug accu-
mulation at a tumor site. This was indeed shown to be true
with SPI-077, where high levels of platinum were detected at
tumor sites [16, 17]. Unfortunately this formulation showed
little activity when evaluated clinically [12]. The limited
therapeuticactivityofthatformulationmatcheswellwiththe
data presented in our paper where a formulation with high
drug retention had the lowest therapeutic activity. Clearly, if
cisplatin retention is so high that the release rate of the drug
at the tumor site is below the therapeutic threshold, then no
antitumor activity will be observed. Also, greater liposome
retention can increase organ exposure and enhance toxicity,
negating the protective eﬀect of liposomal encapsulation. As
the cisplatin release rate is enhanced, more free drug will be
available to the tumor, resulting in cell killing and enhanced
eﬃcacy. For formulation that released cisplatin too quickly
(T1/2 4.5 hours) the opposite problem was observed. In the
high %DP formulation, cisplatin release is occurring rapidly
in the plasma which limits tumor exposure of the drug and
limits the therapeutic eﬀect.
This paper describes the optimization of a liposomal
carrier for enhanced cisplatin therapeutic activity. A lipo-
somal formulation composed of DSPC:DPPC:DSPG:Chol
(35:35:20:10) with an intermediate cisplatin half-life of
8.3 hours demonstrated the greatest eﬃcacy in a P388
murine lymphocytic leukemia model. This optimized for-
mulation has been utilized as part of CPX-571, a ﬁxed-
ratio drug combination of irinotecan and cisplatin. Superior
antitumor activity has been reported for the liposomal
irinotecan:cisplatin combination at a synergistic 7:1 molar
r a t i oc o m p a r e dt of r e ed r u gc o c k t a i li na l lt u m o rm o d e l s
tested [22].6 Chemotherapy Research and Practice
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Figure 4: Accumulation of platinum in the spleen (a), liver (b),
and kidneys (c) of BDF-1 mice (n = 3, Mean ± SD) following the
injectionofcisplatinat3mg/kgasfreedrug();liposomalcisplatin
DSPC:DSPG:CHOL (7:2:1) (light-gray square), or liposomal
cisplatin DSPC:DPPC:DSPG:CHOL (35:35; 20:10) (dark-gray
square).
References
[1] P. T. Daley-Yates and D. C. H. McBrien, “Cisplatin metabolites
in plasma, a study of their pharmacokinetics and importance
in the nephrotoxic and antitumor activity of cisplatin,”
Biochemical Pharmacology, vol. 33, no. 19, pp. 3063–3070,
1984.
[2] S. D. Foss˚ a, S. P. Stenning, A. Gerl et al., “Prognostic factors
in patients progressing after cisplatin-based chemotherapy
for malignant non-seminomatous germ cell tumours,” British
Journal of Cancer, vol. 80, no. 9, pp. 1392–1399, 1999.
[3] D. K. Armstrong, B. Bundy, L. Wenzel et al., “Intraperitoneal
cisplatin and paclitaxel in ovarian cancer,” The New England
Journal of Medicine, vol. 354, no. 1, pp. 34–43, 2006.
[4] A. L. Pinto and S. J. Lippard, “Binding of the antitumor
drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA,”
Biochimica et Biophysica Acta, vol. 780, no. 3, pp. 167–180,
1984.
[ 5 ]M .A .F u e r t e s ,C .A l o n s o ,a n dJ .M .P ´ erez, “Biochemical
modulation of cisplatin mechanisms of action: enhancement
of antitumor activity and circumvention of drug resistance,”
Chemical Reviews, vol. 103, no. 3, pp. 645–662, 2003.
[6] M.A.F ue rt es,J .C astilla,C.A lo nso ,andJ .M.P´ erez,“Cisplatin
biochemical mechanism of action: from cytotoxity to induc-
tion of cell death through interconnections between apoptotic
and necrotic pathways,” Current Medicinal Chemistry, vol. 10,
no. 3, pp. 257–266, 2003.
[7] I. H. Krakoﬀ, “Nephrotoxicity of cis-dichlorodiammine-
platinum(II),” Cancer Treatment Reports, vol. 63, no. 9-10, pp.
1523–1525, 1979.
[8] P. P. Coradini, L. Cigana, S. G. A. Selistre, L. S. Rosito, and A.
L. Brunetto, “Ototoxicity from cisplatin therapy in childhood
cancer,” Journal of Pediatric Hematology/Oncology, vol. 29, no.
6, pp. 355–360, 2007.
[9] I. Arany and R. L. Saﬁrstein, “Cisplatin nephrotoxicity,”
Seminars in Nephrology, vol. 23, no. 5, pp. 460–464, 2003.
[10] R. K. Potkul, J. Gondal, P. Bitterman, K. L. Dretchen, and
A. Rahman, “Toxicities in rats with free versus liposomal
encapsulated cisplatin,” American Journal of Obstetrics and
Gynecology, vol. 164, no. 2, pp. 652–658, 1991.
[11] P. A. Steerenberg, G. Storm, G. de Groot et al., “Liposomes
as drug carrier system for cis-diamminedichloroplatinum(II):
II. Antitumor activity in vivo, induction of drug resistance,
nephrotoxicityandPtdistribution,”CancerChemotherapyand
Pharmacology, vol. 21, no. 4, pp. 299–307, 1988.
[12] S. C. White, P. Lorigan, G. P. Margison et al., “Phase II study
ofSPI-77(stericallystabilisedliposomalcisplatin)inadvanced
non-small-cell lung cancer,” British Journal of Cancer, vol. 95,
no. 7, pp. 822–828, 2006.
[13] T. Boulikas, “Molecular mechanisms of cisplatin and its lipo-
somally encapuslated form, LipoplatinTM as a chemotherapy
and antiangiogenesis drug,” Cancer Therapy, vol. 5, pp. 351–
376, 2007.
[14] F. Lazarioti and T. Boulikas, “Diagnostic and therapeutic
eﬃcacy of imaging modalities in non-small cell lung cancer
(BSCLC):experience from a phase III clinical study using
tumor targeted Lipoplatin nanoparticles,” Cancer Therapy,
vol. 6, pp. 629–646, 2008.
[ 1 5 ]D .M .V a i l ,I .D .K u r z m a n ,P .C .G l a w ee ta l . ,“ S T E A L T H
liposome-encapsulated cisplatin (SPI-77) versus carboplatin
as adjuvant therapy for spontaneously arising osteosarcoma
(OSA) in the dog: a randomized multicenter clinical trial,”
Cancer Chemotherapy and Pharmacology,v o l .5 0 ,n o .2 ,p p .
131–136, 2002.Chemotherapy Research and Practice 7
[16] M. S. Newman, G. T. Colbern, P. K. Working, C. Engbers, and
M.A.Amantea,“Comparativepharmacokinetics,tissuedistri-
bution, and therapeutic eﬀectiveness of cisplatin encapsulated
in long-circulating, pegylated liposomes (SPI-077) in tumor-
bearing mice,” Cancer Chemotherapy and Pharmacology, vol.
43, no. 1, pp. 1–7, 1999.
[17] W. C. Zamboni, A. C. Gervais, M. J. Egorin et al., “Systemic
and tumor disposition of platinum after administration of
cisplatin or STEALTH liposomal-cisplatin formulations (SPI-
077 and SPI-077 B103) in a preclinical tumor model of
melanoma,” Cancer Chemotherapy and Pharmacology, vol. 53,
no. 4, pp. 329–336, 2004.
[18] T. Boulikas, “Low toxicity and anticancer activity of a
novel liposomal cisplatin (Lipoplatin) in mouse xenografts,”
Oncology Reports, vol. 12, no. 1, pp. 3–12, 2004.
[19] T. Boulikas, A. Pantos, E. Bellis, and P. Christoﬁs, “Designing
platinum compounds in cancer: structures and mechanisms,”
Cancer Therapy, vol. 5, pp. 537–583, 2007.
[20] P. G. Tardi, R. C. Gallagher, S. Johnstone et al., “Coencap-
sulation of irinotecan and ﬂoxuridine into low cholesterol-
containing liposomes that coordinate drug release in vivo,”
Biochimica et Biophysica Acta, vol. 1768, no. 3, pp. 678–687,
2007.
[21] P. Tardi,S. Johnstone,N.Harasym et al., “Invivo maintenance
of synergistic cytarabine:daunorubicin ratios greatly enhances
therapeutic eﬃcacy,” Leukemia Research,v o l .3 3 ,n o .1 ,p p .
129–139, 2009.
[22] P. G. Tardi, N. Dos Santos, T. O. Harasym et al., “Drug ratio-
dependent antitumor activity of irinotecan and cisplatin com-
b i n a t i o n si nv i t r oa n di nv i v o , ”Molecular Cancer Therapeutics,
vol. 8, no. 8, pp. 2266–2275, 2009.
[23] L. D. Mayer, M. B. Bally, H. Loughrey, D. Masin, and P.
R. Cullis, “Liposomal vincristine preparations which exhibit
decreased drug toxicity and increased activity against murine
L1210 and P388 tumors,” Cancer Research, vol. 50, no. 3, pp.
575–579, 1990.